Delcath Systems (DCTH) – StreetInsider.com Reports
-
Canaccord Genuity Reiterates Buy Rating on Delcath Systems (DCTH)
-
Delcath Systems (DCTH) PT Raised to $20 at H.C. Wainwright
-
Delcath Systems (DCTH) Tops Q4 EPS by 6c
-
Delcath Systems (DCTH) Appoints Martha S. Rook as Chief Operating Officer
-
Delcath Systems (DCTH) Announces $7M Share Private Placement at $3.72/sh
-
Delcath Systems (DCTH) Announces Healthcare Setting Locator for HEPZATO KIT
-
Delcath Systems (DCTH) Announces COO Resignation
-
Delcath Systems (DCTH) Receives Permanent J-Code for HEPZATO Effective April 1
-
Delcath Systems (DCTH) Misses Q3 EPS by 62c
-
Delcath Systems (DCTH) PT Raised to $21 at Canaccord Genuity
-
Delcath Systems (DCTH) Announces Additional $35M Funding Tied to the FDA Approval of HEPZATO KIT
-
Delcath Systems (DCTH) PT Raised to $18 at H.C. Wainwright
-
Delcath Systems (DCTH) PT Raised to $20 at BTIG
-
Delcath Systems (DCTH) PT Raised to $18 at Canaccord Genuity
-
Delcath Systems (DCTH) Announces FDA Approval of HEPZATO KIT
-
Delcath Systems (DCTH) Misses Q2 EPS by 7c
-
Delcath Systems (DCTH) Appoints Vojislav Vukovic as Chief Medical Officer
-
Delcath Systems (DCTH) Announces 19.5M Share Offering by Selling Stockholders
-
Delcath Systems (DCTH) Announces Sandra Pennell as SVP of Finance
-
Delcath Systems (DCTH) reported Q1 Revenue
-
Delcath Systems (DCTH) reports Q1 results
-
Delcath Systems (DCTH) PT Lowered to $17 at H.C. Wainwright
-
Delcath Systems (DCTH) PT Lowered to $10 at Roth/MKM
-
Delcath Systems (DCTH) Announces up to $85M Financing
-
Delcath Systems (DCTH) Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14
-
Delcath Systems (DCTH) Announces NDA Resubmission for HEPZATO Kit
-
Delcath Systems (DCTH) Announces Publication of Updated Results from CHOPIN Phase 1b Trial
-
Delcath Systems (DCTH) Announces 2.14M Share Offering by Selling Stockholders
-
Insider Buy: Delcath Systems (DCTH) director Salamon buys 15K shares
-
Delcath Systems (DCTH) to Sell 1.45M Shares w/Warrants at $2.90 in Private Placement
-
Delcath Systems (DCTH) PT Lowered to $14 at Canaccord Genuity
-
Delcath Systems (DCTH) Misses Q3 EPS by 3c
-
Delcath Systems (DCTH) Announces Publication of Results of a Multicenter Study of CHEMOSAT
-
Delcath Systems (DCTH) Announces Private Placement of $5 Million of Common Stock, Warrants
-
Delcath Systems (DCTH) Reports Positive Initial Results from CHOPIN Phase 1b Trial
-
Delcath Systems (DCTH) PT Lowered to $16 at Roth Capital
-
Delcath Systems (DCTH) Granted Medical Device Regulation Certification for CHEMOSAT in Europe
-
UPDATE: H.C. Wainwright Starts Delcath Systems (DCTH) at Buy
-
Delcath Systems (DCTH) Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis
-
Delcath Systems (DCTH) Halted, News Pending
-
Delcath Systems (DCTH) Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
-
Delcath Systems (DCTH) CEO Buys ~13K Shares
-
Delcath Systems (DCTH) Files $100M Mixed Shelf
-
Delcath Systems (DCTH) Announces Positive Preliminary Results from FOCUS Trial Presented at the 2021 ASCO Annual Meeting
-
Delcath Systems (DCTH) Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
-
Delcath Systems (DCTH) CEO Buys ~16K Shares
-
Delcath Systems (DCTH) Shares Additional Information Regarding FOCUS Trial Power Calculation
-
Pre-Open Stock Movers 03/31: (SURF) (CHWY) (CASI) Higher; (DCTH) (RMO) (CLSN) Lower (more...)
-
Delcath Systems (DCTH) Erases Gain, Now Down 32%
-
Delcath Systems (DCTH) to Resume Trading at 8 a.m.
Back to DCTH Stock Lookup